The Emerging Role of Cdk5 in Cancer

Trends in Cancer

Volumn 2, Issue 10, 2016, Pages 606-618

  Pozo, Karine ^a   Bibb, James A ^b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

cancer; Cdk5; resistance

Indexed keywords

ANDROGEN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; PEPTIDE; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; CDK5 PROTEIN, HUMAN;

ANGIOGENESIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA REPAIR; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; ANIMAL; DRUG RESISTANCE; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; CELL CYCLE; CYCLIN-DEPENDENT KINASE 5; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84994102504     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.09.001     Document Type: Review

References (92)

1. 1 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
2. 2 Asghar, U., et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 14 (2015), 130–146.
3. 3 Dhavan, R., Tsai, L.H., A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2 (2001), 749–759.
4. 4 Lockwood, W.W., et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 27 (2008), 4615–4624.
5. 5 Harada, T., et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 27 (2008), 1951–1960.
6. 6 Eggers, J.P., et al. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clin. Cancer Res. 17 (2011), 6140–6150.
7. 7 Choi, H.S., et al. Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population. J. Hum. Genet. 54 (2009), 298–303.
8. 8 Kibel, A.S., et al. Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma. Prostate 76 (2016), 479–490.
9. 9 Wei, K., et al. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker. World J. Surg. Oncol., 14, 2016, 34.
10. 10 Meder, L., et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int. J. Cancer 138 (2016), 927–938.
11. 11 Liu, J.L., et al. Cyclin-dependent kinase 5 regulates the proliferation, motility and invasiveness of lung cancer cells through its effects on cytoskeletal remodeling. Mol. Med. Rep. 12 (2015), 3979–3985.
12. 12 Pozo, K., et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell 24 (2013), 499–511.
13. 13 Xie, W., et al. Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas. Oncotarget., 2016, 10.18632/oncotarget.10550 Published online July 12, 2016.
14. 14 Liu, J.L., et al. Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Med. Oncol. 28 (2011), 673–678.
15. 15 Liang, Q., et al. CDK5 is essential for TGF-beta1-induced epithelial-mesenchymal transition and breast cancer progression. Sci. Rep., 3, 2013, 2932.
16. 16 Chiker, S., et al. Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients. Cell Cycle 14 (2015), 3066–3078.
17. 17 Catania, A., et al. Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells. Neuro. Oncol. 3 (2001), 89–98.
18. 18 Yushan, R., et al. Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study. World J. Surg. Oncol., 13, 2015, 223.
19. 19 Zhang, X., et al. Aberrant expression of CDK5 infers poor outcomes for nasopharyngeal carcinoma patients. Int. J. Clin. Exp. Pathol. 8 (2015), 8066–8074.
20. 20 Cao, L., et al. Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis. Clin. Cancer Res. 21 (2015), 1419–1428.
21. 21 Lu, J.W., et al. Decreased expression of p39 is associated with a poor prognosis in human hepatocellular carcinoma. Med. Oncol. 28:Suppl 1 (2011), S239–S245.
22. 22 Lopes, J.P., Agostinho, P., Cdk5: multitasking between physiological and pathological conditions. Prog. Neurobiol. 94 (2011), 49–63.
23. 23 Futatsugi, A., et al. Cyclin-dependent kinase 5 regulates E2F transcription factor through phosphorylation of Rb protein in neurons. Cell Cycle 11 (2012), 1603–1610.
24. 24 Ogara, M.F., et al. CDK5-mediated phosphorylation of p19INK4d avoids DNA damage-induced neurodegeneration in mouse hippocampus and prevents loss of cognitive functions. Biochim. Biophys. Acta 1843 (2014), 1309–1324.
25. 25 Chang, K.H., et al. Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death. J. Cell Sci. 125 (2012), 5124–5137.
26. 26 Fu, A.K., et al. Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 6728–6733.
27. 27 Lin, H., et al. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. J. Biol. Chem. 282 (2007), 2776–2784.
28. 28 Hsu, F.N., et al. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser(7)(2)(7) on STAT3 in prostate cancer cells. Am. J. Physiol. Endocrinol. Metab. 305 (2013), E975–E986.
29. 29 Lin, H., et al. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. J. Biol. Chem. 279 (2004), 29302–29307.
30. 30 Lindqvist, J., et al. Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells. Mol. Biol. Cell 26 (2015), 1971–1984.
31. 31 Goldstein, M., Kastan, M.B., The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu. Rev. Med. 66 (2015), 129–143.
32. 32 Turner, N.C., et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27 (2008), 1368–1377.
33. 33 Courapied, S., et al. The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J. Biol. Chem. 285 (2010), 26765–26778.
34. 34 Ehrlich, S.M., et al. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma – a novel therapeutic approach. J. Hepatol. 63 (2015), 102–113.
35. 35 Yu, H.P., et al. TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway. Sci. Rep., 5, 2015, 9853.
36. 36 Lee, J.H., Kim, K.T., Regulation of cyclin-dependent kinase 5 and p53 by ERK1/2 pathway in the DNA damage-induced neuronal death. J. Cell Physiol. 210 (2007), 784–797.
37. 37 Tian, B., et al. Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death. Nat. Cell Biol. 11 (2009), 211–218.
38. 38 Vigneron, A., et al. The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res. 68 (2008), 815–825.
39. 39 Bolin, C., et al. The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation. Cell Mol. Life Sci. 69 (2012), 951–962.
40. 40 Zhang, F., et al. Enhancement of radiosensitivity by roscovitine pretreatment in human non-small cell lung cancer A549 cells. J. Radiat. Res. 49 (2008), 541–548.
41. 41 Bhandari, D., et al. Cyclin-dependent kinase 5 activates guanine nucleotide exchange factor GIV/Girdin to orchestrate migration-proliferation dichotomy. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E4874–E4883.
42. 42 Demelash, A., et al. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol. Biol. Cell 23 (2012), 2856–2866.
43. 43 Strock, C.J., et al. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res. 66 (2006), 7509–7515.
44. 44 Feldmann, G., et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol. Ther. 12 (2011), 598–609.
45. 45 Bisht, S., et al. Cyclin-dependent kinase 5 (CDK5) controls melanoma cell motility, invasiveness, and metastatic spread – identification of a promising novel therapeutic target. Transl. Oncol. 8 (2015), 295–307.
46. 46 Herzog, J., et al. Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1alpha: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma. Oncotarget 7 (2016), 27108–27121.
47. 47 Sharma, M.R., et al. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J. Cell Biochem. 91 (2004), 398–409.
48. 48 Liebl, J., et al. Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J. Biol. Chem. 285 (2010), 35932–35943.
49. 49 Merk, H., et al. Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis. Oncotarget 7 (2016), 6088–6104.
50. 50 de Nigris, F., et al. Osteosarcoma cells induce endothelial cell proliferation during neo-angiogenesis. J. Cell. Physiol. 228 (2013), 846–852.
51. 51 Weitensteiner, S.B., et al. Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. PLoS One, 8, 2013, e54607.
52. 52 Liebl, J., et al. Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2. Nat. Commun., 6, 2015, 7274.
53. 53 Peyressatre, M., et al. Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers (Basel) 7 (2015), 179–237.
54. 54 Cicenas, J., et al. Roscovitine in cancer and other diseases. Ann. Transl. Med., 3, 2015, 135.
55. 55 Karran, E., Palmer, A.M., Neurodegenerative disorders and their treatment. Drug News Perspect. 20 (2007), 407–412.
56. 56 Weishaupt, J.H., et al. Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction. Mol. Cell Neurosci. 24 (2003), 489–502.
57. 57 Plattner, F., et al. Memory enhancement by targeting Cdk5 regulation of NR2B. Neuron 81 (2014), 1070–1083.
58. 58 Plattner, F., et al. The role of ventral striatal cAMP signaling in stress-induced behaviors. Nat. Neurosci. 18 (2015), 1094–1100.
59. 59 Wissing, M.D., et al. Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression. Oncol. Rep. 32 (2014), 419–424.
60. 60 Shi, Z., et al. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res. 73 (2013), 5519–5531.
61. 61 Ren, Y., et al. AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis. Cancer Lett. 362 (2015), 174–182.
62. 62 Dorand, R.D., et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353 (2016), 399–403.
63. 63 Liebl, J., et al. Twice switched at birth: cell cycle-independent roles of the “neuron-specific” cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells. Cell Signal. 23 (2011), 1698–1707.
64. 64 Arif, A., Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5. Biochem. Pharmacol. 84 (2012), 985–993.
65. 65 Brinkkoetter, P.T., et al. Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. J. Clin. Investig. 119 (2009), 3089–3101.
66. 66 Li, R., et al. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer. Eur. Rev. Med. Pharmacol. Sci. 19 (2015), 4533–4541.
67. 67 Hisanaga, S., Saito, T., The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. Neurosignals 12 (2003), 221–229.
68. 68 Lindqvist, J., et al. Studying nestin and its interrelationship with Cdk5. Methods Enzymol. 568 (2016), 509–535.
69. 69 Takashima, A., et al. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci. Lett. 306 (2001), 37–40.
70. 70 Rouzier, R., et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 8315–8320.
71. 71 Grant, N.J., et al. Phosphorylatiojn of a splice variant of collapsin response mediator protein 2 in the nucleus of tumour cells links cyclin dependent kinase-5 to oncogenesis. BMC Cancer, 15, 2015, 885.
72. 72 Hayashi, K., et al. Phosphorylation of the tubulin-binding protein, stathmin, by Cdk5 and MAP kinases in the brain. J. Neurochem. 99 (2006), 237–250.
73. 73 Nie, W., et al. Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer. Lab. Invest. 95 (2015), 56–64.
74. 74 Huang, C., et al. Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration. Nat. Cell Biol. 11 (2009), 624–630.
75. 75 Quintavalle, M., et al. A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion. Sci. Signal., 4, 2011, ra49.
76. 1 cell cycle arrest and apoptosis. PLoS One, 10, 2015, e0131833.
77. 77 Mimori, K., et al. Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br. J. Cancer 94 (2006), 1894–1897.
78. 78 Kim, E., et al. CDK5 is a novel regulatory protein in PPARgamma ligand-induced antiproliferation. Int. J. Oncol. 28 (2006), 191–194.
79. 79 Lowman, X.H., et al. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol. Cell 40 (2010), 823–833.
80. 80 Leshchenko, V.V., et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 116 (2010), 1025–1034.
81. 81 Levacque, Z., et al. Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients. Cell Cycle 11 (2012), 4093–4095.
82. 82 Hsu, F.N., et al. Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J. Biol. Chem. 286 (2011), 33141–33149.
83. 83 Huang, E., et al. The role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death. Nat. Cell Biol. 12 (2010), 563–571.
84. 84 Tripathi, B.K., et al. CDK5 is a major regulator of the tumor suppressor DLC1. J. Cell. Biol. 207 (2014), 627–642.
85. 85 Xie, Z., et al. Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration. Cell 114 (2003), 469–482.
86. 86 Filippova, N., et al. Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function. J. Biol. Chem. 287 (2012), 32277–32287.
87. 87 Rashid, T., et al. Phosphorylation of Pak1 by the p35/Cdk5 kinase affects neuronal morphology. J. Biol. Chem. 276 (2001), 49043–49052.
88. 88 Lee, J.H., et al. Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J. Cell Sci. 120 (2007), 2259–2271.
89. 89 Ajay, A.K., et al. Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression. Mol. Cancer, 9, 2010, 204.
90. 90 Liu, R., et al. Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 7570–7575.
91. 91 Lee, K.Y., et al. Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein. J. Biol. Chem. 272 (1997), 5622–5626.
92. 92 Xie, W., et al. CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression. Int. J. Biol. Sci. 10 (2014), 192–199.